ROCKET PHARMACEUTICALS, INC.
RCKTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$231.7M | −$273.2M | −$259.7M | −$224.3M | −$167.2M | −$134.3M |
| Net income | −$223.1M | −$258.7M | −$245.6M | −$221.9M | −$169.1M | −$139.7M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M | $590.8M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M | $87.3M |
| Equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M | $503.5M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 |
| Shares out. | 106.6M | 90.5M | 79.3M | 64.5M | 61.8M | 55.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −80.5%
- Return on assets
- −67.5%
- Return on capital (ROCE)
- −77.2%
- Liabilities / assets
- 16.1%
- Debt / equity
- 0.19×
- Book value / share
- $2.60
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.24distress
- Accruals / assets
- −10.0%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-05-05Gene Therapy for Fanconi Anemia, Complementation Group A
- Phase 2Recruitingreadout ~2028-04A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
- Phase 1Recruitingreadout ~2028-09A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
- Phase 1Recruitingreadout ~2029-06A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 27, 2026
- Maverick Capital LtdPassive (13G)Feb 13, 2026
- Wellington Management Group LlpPassive (13G)Jun 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 20.9M | 10.1 | -2.8% |
| Apr 30, 2026 | 21.5M | 10.7 | +13.0% |
| Apr 15, 2026 | 19.1M | 7.3 | +2.7% |
| Mar 31, 2026 | 18.6M | 2.9 | +26.5% |
| Mar 13, 2026 | 14.7M | 4.3 | +5.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 21, 2026
- Results of operationsMay 7, 2026
- Entered a material agreement · Regulation FD disclosureApr 28, 2026
- Regulation FD disclosureMar 27, 2026
- Entered a material agreement · Terminated a material agreementMar 10, 2026
- Results of operationsFeb 26, 2026
- Results of operationsNov 6, 2025
- Other material eventOct 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.